Bio-Techne Corporation

NasdaqGS:TECH Stock Report

Market Cap: US$10.3b

Bio-Techne Valuation

Is TECH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of TECH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: TECH ($66.78) is trading below our estimate of future cash flow value ($74.3)

Significantly Below Future Cash Flow Value: TECH is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TECH?

Key metric: As TECH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TECH. This is calculated by dividing TECH's market cap by their current earnings.
What is TECH's PE Ratio?
PE Ratio128.9x
EarningsUS$81.06m
Market CapUS$10.30b

Price to Earnings Ratio vs Peers

How does TECH's PE Ratio compare to its peers?

The above table shows the PE ratio for TECH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.1x
QGEN Qiagen
24.7x9.84%US$10.6b
ICLR ICON
19.2x11.90%US$11.1b
RVTY Revvity
48x22.47%US$11.3b
WST West Pharmaceutical Services
36.4x10.37%US$16.7b
TECH Bio-Techne
128.9x23.24%US$10.3b

Price-To-Earnings vs Peers: TECH is expensive based on its Price-To-Earnings Ratio (128.9x) compared to the peer average (32.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does TECH's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
TECH 128.9xIndustry Avg. 36.5xNo. of Companies3PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TECH is expensive based on its Price-To-Earnings Ratio (128.9x) compared to the North American Life Sciences industry average (35.8x).

Price to Earnings Ratio vs Fair Ratio

What is TECH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TECH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio128.9x
Fair PE Ratio25.4x

Price-To-Earnings vs Fair Ratio: TECH is expensive based on its Price-To-Earnings Ratio (128.9x) compared to the estimated Fair Price-To-Earnings Ratio (25.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TECH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$66.78
US$74.27
+11.22%
6.84%US$80.00US$65.00n/a11
Jan ’27US$58.81
US$69.67
+18.46%
6.72%US$75.00US$60.00n/a12
Dec ’26US$63.76
US$69.17
+8.48%
6.83%US$75.00US$60.00n/a12
Nov ’26US$62.57
US$67.83
+8.41%
8.23%US$75.00US$59.00n/a12
Oct ’26US$59.92
US$65.67
+9.59%
10.32%US$75.00US$53.00n/a12
Sep ’26US$54.63
US$65.31
+19.55%
10.15%US$75.00US$53.00n/a13
Aug ’26US$54.89
US$66.50
+21.15%
11.95%US$80.00US$55.00n/a14
Jul ’26US$52.08
US$67.28
+29.19%
16.07%US$90.00US$51.00n/a13
Jun ’26US$48.40
US$69.26
+43.09%
17.34%US$90.00US$51.00n/a13
May ’26US$49.63
US$79.70
+60.58%
15.36%US$95.00US$51.00n/a12
Apr ’26US$57.35
US$83.87
+46.25%
10.94%US$95.00US$68.00n/a13
Mar ’26US$61.75
US$85.42
+38.33%
9.15%US$95.00US$68.00n/a13
Feb ’26US$73.55
US$85.42
+16.13%
6.70%US$95.00US$75.00US$64.0913
Jan ’26US$72.03
US$85.26
+18.37%
6.72%US$95.00US$75.00US$58.8113
Dec ’25US$75.36
US$85.25
+13.12%
6.72%US$95.00US$75.00US$63.7613
Nov ’25US$75.31
US$85.25
+13.20%
6.72%US$95.00US$75.00US$62.5713
Oct ’25US$78.17
US$83.09
+6.30%
8.27%US$95.00US$65.00US$59.9213
Sep ’25US$73.99
US$82.55
+11.57%
9.17%US$95.00US$65.00US$54.6313
Aug ’25US$82.35
US$83.63
+1.56%
9.20%US$95.00US$65.00US$54.8913
Jul ’25US$71.61
US$84.02
+17.32%
9.66%US$95.00US$65.00US$52.0813
Jun ’25US$77.19
US$84.02
+8.84%
9.66%US$95.00US$65.00US$48.4013
May ’25US$73.46
US$81.38
+10.78%
10.33%US$95.00US$65.00US$49.6311
Apr ’25US$69.41
US$80.32
+15.72%
8.61%US$95.00US$65.00US$57.3513
Mar ’25US$74.38
US$80.32
+7.99%
8.61%US$95.00US$65.00US$61.7513
Feb ’25US$68.54
US$80.61
+17.61%
9.19%US$95.00US$65.00US$73.5512
US$74.27
Fair Value
10.1% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/06 11:05
End of Day Share Price 2026/02/06 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Techne Corporation is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Catherine Ramsey SchulteBaird
Robert WassermanBenchmark Company